<html xmlns:fo="http://www.w3.org/1999/XSL/Format">

<!-- Mirrored from www.zambiahivguide.org/drugs/antiretrovirals/full_enfuvirtide.html by HTTrack Website Copier/3.x [XR&CO'2007], Thu, 19 Jun 2008 21:24:50 GMT -->
<head>
<META http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<title>Johns Hopkins POC-IT: Point of Care Information Technology</title>
<meta content="text/html; charset=iso-8859-1" http-equiv="Content-Type">
<link href="../../images/styles.css" type="text/css" rel="stylesheet">
<script type="text/JavaScript" src="../../images/functions.js" language="JavaScript"></script>
</head>
<body>
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td>Johns Hopkins POC-IT: Point of Care Information Technology</td><td >
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td >
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td></td><td>
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td class="tdVAlignMiddle" align="center" >
                                                            &nbsp;</td>
</tr>
<tr></tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
<tr>
<td  ><span class="mainNav">&nbsp;Print-Friendly Module</span></td>
</tr>
</table>
</td>
</tr>
</table>
<p></p>
<table cellspacing="0" cellpadding="0" border="0" >
<tr>
<td></td><td>
<table >
<tr>
<td><span class="primaryItemTitle"><font size="6">Enfuvirtide</font></span>
<br>
</td><td align="right" valign="top"><a href="javascript:window.print();"></a></td>
</tr>
<tr>
<td colspan="2">
<br>
        Author: <author maxOccurance="1" tag="author" use="required">Paul A. Pham, Pharm.D. and John G. Bartlett, M.D. </author>
<br>
<span class="display_date">04-25-2008</span>
<br>
<div style="background-color:#ccffcc;">
<a name=""></a>
<h2 class="grayLineHeaderBar"></h2>
<ul>
<li>Currently not available in Zambia. </li>
<li>Active against PI-, NNRTI-, and NRTI-resistance virus, but very expensive and requires twice-daily subcutaneous administration. </li>
</ul>Zambia Information Author: Paul A. Pham, Pharm. D. <br>
<br>
</div>
<a name="INDICATIONS"></a>
<h2 class="grayLineHeaderBar">INDICATIONS</h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">FDA</span></td>
</tr>
</table>
<hr>
<ul>
<li>Enfuvirtide in combination with other antiretroviral agents is indicated for the treatment of HIV-1 infection in treatment-experienced pts with evidence of HIV-1 replication despite ongoing antiretroviral therapy.</li>
</ul>
<a name="FORMS"></a>
<h2 class="grayLineHeaderBar">FORMS</h2>
<TABLE  class="blueOutline" cellspacing="0" cellpadding="2" border="0">
<TR class="blueBarBG">
<TD><B>brand name</B></TD><TD><B>preparation</B></TD><TD><B>manufacturer</B></TD><TD><B>route</B></TD><TD><B>form</B></TD><TD><B>dosage^</B></TD><TD><B>cost*</B></TD>
</TR>
        
<TR>
<TD valign="top">
            <I>Fuzeon </I>
          </TD><TD valign="top">Enfuvirtide (ENF&lt; T20) </TD><TD valign="top">Roche </TD><TD>
                SC 
              </TD><TD>Vial </TD><TD>90 mg </TD><TD>$40.52</TD>
</TR>
      
</TABLE>
<p>*Costs (rounded to the nearest dollar) are based on usual adult dosing per day, 
                are representative of "Average Wholesale Price" (AWP), and are current within the prior three months.</p>
<p>^Dosage is indicated in mg unless otherwise noted.</p>
<a name="USUAL ADULT DOSING"></a>
<h2 class="grayLineHeaderBar">USUAL ADULT DOSING</h2>
<ul>
<li>90 mg (1 mL) SC q12h into upper arm, anterior thigh or abdomen with each injection given at a site different from the preceding injection site. Do not inject where large nerves course close to skin, over a blood vessel, into moles, scar tissue, tattoos, burn sites, or around the navel.</li>
<li>Prior to administration, reconstitute with 1.1 mL of sterile water, giving a volume of 1.2 mL. </li>
<li>Once reconstituted it must be refrigerated and used within 24 hrs. </li>
</ul>
<a name="RENAL DOSING"></a>
<h2 class="grayLineHeaderBar">RENAL DOSING</h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF 50-80</span></td>
</tr>
</table>
<hr>90 mg SC q12h <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF 10-50</span></td>
</tr>
</table>
<hr>&gt;35-50 mL/min: No significant change in PK parameters. Usual dose likely. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF &lt;10 ML/MIN</span></td>
</tr>
</table>
<hr>&lt;35 mL/min: No data, usual dose likely. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN HEMODIALYSIS</span></td>
</tr>
</table>
<hr>No data, usual dose likely. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN PERITONEAL DIALYSIS</span></td>
</tr>
</table>
<hr>No data, usual dose likely. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN HEMOFILTRATION</span></td>
</tr>
</table>
<hr>No data. <br>
<br>
<a name="ADVERSE DRUG REACTIONS"></a>
<h2 class="grayLineHeaderBar">ADVERSE DRUG REACTIONS</h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">COMMON</span></td>
</tr>
</table>
<hr>
<ul>
<li>Local site reaction (grade 3 or 4) including pain (9%), erythema (32%), pruritus (4%), induration (57%), and nodules or cysts (26%), leading to discontinuation in 3%.</li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">OCCASIONAL</span></td>
</tr>
</table>
<hr>
<ul>
<li>Eosinophilia</li>
<li>Bacterial pneumonia (4.68 vs. 0.61 events per 100 pts-yr in treatment and control arms, respectively).</li>
<li>With use of Biojector needle-free device: nerve pain (neuralgia and/or paresthesia) lasting up to 6 months at anatomical sites where large nerves course close to the skin; bruising; hematomas. </li>
</ul>
<a name="DRUG INTERACTIONS"></a>
<h2 class="grayLineHeaderBar">DRUG INTERACTIONS</h2>
<ul>
<li>Not an inhibitor or inducer CYP3A4, CYP2D6, CYP1A2, CYP2C19 or CYP2E1 substrates. As expected, ENF does not interact with <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A>, <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>, or <A class="headLines" target="_new" href="../antimicrobial_agents/rifampicin532e.html?contentInstanceId=434653">rifampin</A>. </li>
<li>In an observational study, <A class="headLines" target="_new" href="tipranavir9ea2.html?contentInstanceId=443122">TPV</A> Cmin was increased by approx. 50% with ENF co-administration. Critical factor such as food-effect and adherence were not objectively measured.&nbsp;Limitations of the study design could also have affected results . </li>
</ul>
<a name="RESISTANCE"></a>
<h2 class="grayLineHeaderBar">RESISTANCE</h2>
<ul>
<li>No cross-resistance with NRTIs, NNRTIs, or PIs. <I>In vitro</I>, clinical isolates resistant to NRTI, NNRTI, or PIs retained susceptibility to ENF.</li>
<li>A 21-fold (range, &lt;1- 422-fold) decrease in susceptibility to ENF has been correlated with genotypic changes in gp41 amino acids 36-45 (36, 38, 40, 42, 43, and 45).</li>
</ul>
<a name="PHARMACOLOGY"></a>
<h2 class="grayLineHeaderBar">PHARMACOLOGY</h2>
<a name="N1083E"></a>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">MECHANISM</span></td>
</tr>
</table>
<hr>ENF binds to HR1 site in gp41 subunit of the viral envelope glycoprotein and prevents conformational change required for viral fusion and entry into cells.<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">PHARMACOKINETIC PARAMETERS</span></td>
</tr>
</table>
<hr>
<ul>
<li>Absorption: 
                Well absorbed from SC site with bioavailability of 84.3% (+/- 15.5%). </li>
<li>Metabolism and Excretion: 
                Undergoes catabolism. Exact pathway of ENF metabolism is unknown. <I>In vitro</I>, undergoes a non-NADPH dependent hydrolysis.</li>
<li>Protein Binding: 
                92%</li>
<li>Cmax, Cmin, and AUC: 
                Following 90 mg SC, mean Cmax was 5.0 +/-1.7 mcg/mL, Cmin was 3.3+/-1.6 mcg/mL, and AUC was 48.7 +/- 19.1 mcg/mL hr. Cmin 2.2 mcg/mL was associated with virologic suppression (Bonora S et al. CROI 2005 abstract 643)</li>
<li>T1/2: 
                3.8 +/- 0.6 h</li>
<li>Distribution: 
                Vd=5.5 +/- 1.1L </li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR DECREASED HEPATIC FUNCTION</span></td>
</tr>
</table>
<hr>No data.<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">PREGNANCY RISK</span></td>
</tr>
</table>
<hr>Category B: not teratogenic in animal studies. No human data.<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">BREAST FEEDING COMPATIBILITY</span></td>
</tr>
</table>
<hr>No data. Breastfeeding not recommended in the U.S.<a name="COMMENTS"></a>
<h2 class="grayLineHeaderBar">COMMENTS</h2>
<ul>
<li>Pros: Active against PI-, NNRTI-, and NRTI-resistance virus; good response if background regimen includes <U>&gt;</U>2 active ARTs; well studied in ART-experienced pts.</li>
<li>Cons: SC administration; injection site reactions; time consuming reconstitution process; expensive; requires extensive pt education and training. </li>
</ul>
<a name="N10886"></a><a name="References"></a>
<h2 class="grayLineHeaderBar">References</h2>
<ol>
<li>Lazzarin A, Queiroz-Telles F, Frank I, et al. et al. ;
		TMC 114/r provides durable viral load suppression in treatment-experienced patients: POWER 1 and 2 combined Week 48 analysis. ;        
		Presented at the 16th International AIDS Conference, August 13-18m 2006, Toronto, Canada. ;
		2006; Vol. 
		<br>
<b>Comments:</b>61% of DRV/r-treated pts and 15% of control pts achieved &gt;1 log reduction in VL though wk 48. VL &lt;50 achieved in 46% and 10% of DRV/r and control pts, respectively (p&lt;0.003). <A class="headLines" target="_new" href="darunavir4a48.html?contentInstanceId=443123">Darunavir</A>-treated pts who were naive to ENF had a significantly greater VL if they included ENF in their background regimen. 21/36 achieved a VL reduction of at least 1 log, compared with only 4/35 ENF-naive pts who did not receive DRV/r. <br>
<br>
</li>
<li>Hicks CB, Cahn P, Cooper DA, et al.;
		Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.;        
		Lancet;
		2006; Vol. 
		368; pp. 
		466-75;
		<br>ISSN:
	        	1474-547X;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=16890833&amp;dopt=abstract" target="_new">16890833 </a>
<br>
<b>Comments:</b>Similar to the <A class="headLines" target="_new" href="darunavir4a48.html?contentInstanceId=443123">DRV</A> studies, pts on TPV/r + an OB regimen that included ENF had a better virologic response rate (VL reduction of 1.67log vs 0.98 log) <br>
<br>
</li>
<li>Lalezari JP, Henry K, O'Hearn M, et al.;
		Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.;        
		N Engl J Med;
		2003; Vol. 
		348; pp. 
		2175-85;
		<br>ISSN:
	        	1533-4406;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=12637625&amp;dopt=abstract" target="_new">12637625</a>
<br>
<b>Comments:</b>Pooled data presented to FDA from 2 randomized, controlled, open-label studies (TORO 1 and TORO 2) involving 995 treatment-experienced pts. ENF + an optimized background (OB) regimen superior to OB regimen alone. Pts had baseline VL of 5.2 logs, mean of 12 prior ART agents, and 80-90% had &gt;5 resistance mutations to NRTIs, NNRTIs, or PIs. VL change from baseline to wk 24 was -1.52 log for pts receiving ENF + OB regimen arm compared to -0.73 log in OB arm. As expected, pts with &gt;2 active agents in their OB regimen more likely to achieve undetectable VL. <br>
<br>
</li>
</ol>
<br>
</td>
</tr>
</table>
</td><td></td>
</tr>
</table>
<p></p>
<table cellpadding="0" cellspacing="0" border="0" >
<tr>
<td bgcolor="#003366"></td><td class="bottomNav" bgcolor="#003366" >
<center>
<span class="copyrightFullModule">Copyright 2000-2008 Johns Hopkins University.  All rights reserved.</span>
</center>
</td>
</tr>
</table>
</body>

<!-- Mirrored from www.zambiahivguide.org/drugs/antiretrovirals/full_enfuvirtide.html by HTTrack Website Copier/3.x [XR&CO'2007], Thu, 19 Jun 2008 21:24:50 GMT -->
</html>
